Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

TM Ma, JM Lamb, M Casado, X Wang, TV Basehart… - BMC cancer, 2021 - Springer
Background Stereotactic body radiotherapy (SBRT) is becoming increasingly used in
treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy …

Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III …

AU Kishan, J Lamb, M Casado, X Wang, TM Ma, D Low… - 2022 - ascopubs.org
255 Background: Magnetic resonance imaging (MRI) guidance offers several theoretical
advantages over computed tomography (CT) guidance in the context of stereotactic body …

Magnetic resonance imaging–guided vs computed tomography–guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial

AU Kishan, TM Ma, JM Lamb, M Casado… - JAMA …, 2023 - jamanetwork.com
Importance Magnetic resonance imaging (MRI) guidance offers multiple theoretical
advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer …

1.5 T magnetic resonance-guided stereotactic body radiotherapy for localized prostate cancer: preliminary clinical results of clinician-and patient-reported outcomes

DMC Poon, J Yuan, OL Wong, B Yang, ST Chiu… - Cancers, 2021 - mdpi.com
Simple Summary The combination of stereotactic body radiotherapy (SBRT) and magnetic
resonance-guided radiation therapy (MRgRT) offers the potential for achieving better tumor …

Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body …

JE Leeman, KY Shin, YH Chen, RH Mak, PL Nguyen… - Cancer, 2023 - Wiley Online Library
Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate
cancer management but there remain significant toxicity risks when delivering prostate …

Magnetic resonance image-guided adaptive stereotactic body radiotherapy for prostate cancer: preliminary results of outcome and toxicity

G Ugurluer, B Atalar, T Zoto Mustafayev… - The British journal of …, 2021 - academic.oup.com
Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic
body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been …

Non-adaptive MR-guided radiotherapy for prostate SBRT: Less time, equal results

ML Sandoval, I Youssef, K Latifi, GD Grass… - Journal of Clinical …, 2021 - mdpi.com
Background: The use of stereotactic body radiation therapy (SBRT) is widely utilized for
treatment of localized prostate cancer. Magnetic-resonance-guided radiotherapy (MRgRT) …

Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial

J Ristau, J Hörner-Rieber, C Buchele, S Klüter… - Radiation …, 2022 - Springer
Background Normofractionated radiation regimes for definitive prostate cancer treatment
usually extend over 7–8 weeks. Recently, moderate hypofractionation with doses per …

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low-and intermediate-risk prostate cancer: early results

S Aluwini, P van Rooij, M Hoogeman, W Kirkels… - Radiation …, 2013 - Springer
Background There is growing evidence that prostate cancer (PC) cells are more sensitive to
high fraction dose in hypofractionation schemes. High-dose-rate (HDR) brachytherapy as …

Magnetic resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on patient-reported outcomes of a prospective phase 2 study

SU Tetar, AME Bruynzeel, SS Oei, S Senan… - European Urology …, 2021 - Elsevier
Background The recent introduction of magnetic resonance-guided radiation therapy
(MRgRT) has allowed improved treatment planning and delivery of stereotactic body …